Lilly’s Mounjaro Enters China’s State Insurance System
Eli Lilly achieved a major market access milestone after Mounjaro was officially added to China’s national medical insurance list for diabetes treatment, dramatically improving affordability and penetration prospects across the country. The inclusion allows millions of Chinese patients with type 2 diabetes to access tirzepatide at reimbursed prices for the first time, accelerating domestic adoption. The decision also strengthens Lilly’s competitive position against Novo Nordisk in the world’s largest diabetes market. Industry analysts view the move as a turning point for high-end metabolic biologics in China’s reimbursement system, signaling a broader willingness to cover premium innovation.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-06-26
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
-
India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence
-
Roche Takes Natco to Supreme Court Over Generic Risdiplam Launch in India
-
Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy
-
Aspen Secures Approval to Market Lilly’s Mounjaro for Weight Loss in South Africa
-
Bayer’s Ambitious Gene & Cell Therapy Pipeline Eyes Parkinson’s, Oncology, Rare Diseases
-
J&J to Spin Off Orthopedics Business, Raises 2025 Forecast
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
Biological E Partners with Recbio to Bring HPV9 Vaccine to India and Global Markets
-
NATO Fund Invests $35 Million in Biotech Startup to Counter Biological Threats
Recommend Reading
-
Pharma Companies to See 11 Percent Growth in Sales and EBITDA in Q1FY26
-
Sipcam Nichino Brasil Unveils Soleado Fungicide at Hortitec 2025
-
Alchem Fined $576,000 for Role in EU Pharmaceutical Cartel
-
Merck’s New CMV Drug Approved in China Targets Nearly 40000 HSCT Patients
-
Over 100 Foreign Pharma Executives Join Chinese Firms in 5 Years Industry Faces Key Challenges
-
“The 40-Year Ethylene Giant Collapses”: ExxonMobil’s Premature Shutdown Is Not Just Scotland’s Tragedy—It’s the Twilight Elegy of European Industrial Civilization
-
Uses and Benefits of Sodium Selenite
-
Notice of 2026 Chinese New Year Holiday
-
DMF Inventory Remains High, Prices Stay Stable
-
Polyethylene Weakens with Fluctuations, Trading Remains Light Before the Chinese New Year